Literature DB >> 23125063

Mitomycin-augmented non-penetrating deep sclerectomy: preoperative gonioscopy and postoperative perimetric, tonometric and medication trends.

William Eric Sponsel1, Sylvia Linner Groth.   

Abstract

BACKGROUND/AIMS: Non-penetrating deep sclerectomy (NPDS) can enhance drainage of aqueous humour without disrupting the trabecular endothelial layer, reducing risks of postoperative hypotony and hyphema. This study explores associations of angle morphology with surgical efficacy in eyes with open and obstructed angles.
METHODS: Eighty-nine consecutive eyes undergoing successful NPDS (non-implant, with 0.4 mg/ml mitomycin C and limbus-based two-layer closure) were studied in this institutional review board-approved retrospective quality assurance study. Postoperative complication frequency, intraocular pressure (IOP), glaucoma medications required and acuity were monitored (baseline vs 3, 6, 9, 12 and 18-month postoperative levels), along with 30-2 Humphrey MD and corrected pattern standard deviation (CPSD) (baseline vs 6, 12 and 18-month postoperative values). Preoperative gonioscopy was compared with the subsequent requirement for specific postoperative interventions.
RESULTS: IOP at all five postoperative intervals was reduced (22 ± 0.9 to 12 ± 0.5 mm Hg; p<0.0001). No hyphema were observed. Postoperative hypotony (IOP < 4 mm Hg) occurred rarely (8/445; 1.8%). Mean glaucoma medication use dropped from 3.1 ± 0.1 to 0.23 ± 0.1 at 18 months (p<0.0001). Mean 30-2 MD improved by approximately 1.4 dB at 6, 12 and 18 months (p<0.002); CPSD remained stable.
CONCLUSIONS: Following NPDS, a sustained IOP decrease of 10 mm Hg (45%) was attained, with stable acuity, increased perimetric generalised light sensitivity and 90% reduction in medical therapy requirement. Morbidity risk was associated with narrow gonioscopic angle insertion and synechia, but not with shallow approach or trabecular pigmentation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23125063     DOI: 10.1136/bjophthalmol-2012-301886

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  6 in total

1.  Risk assessment of sudden visual loss following non-penetrating deep sclerectomy in severe and end-stage glaucoma.

Authors:  Igor Leleu; Benjamin Penaud; Esther Blumen-Ohana; Thibault Rodallec; Raphaël Adam; Olivier Laplace; Jad Akesbi; Jean-Philippe Nordmann
Journal:  Eye (Lond)       Date:  2019-01-24       Impact factor: 3.775

2.  Clinical outcomes after Ex-PRESS glaucoma shunt versus non-penetrating deep sclerectomy: two-year follow-up.

Authors:  Beatriz Puerto; Cristina López-Caballero; Carmen Sánchez-Sánchez; Noelia Oblanca; Vanesa Blázquez; Inés Contreras
Journal:  Int Ophthalmol       Date:  2017-11-24       Impact factor: 2.031

3.  Central 10-degree visual field change following non-penetrating deep sclerectomy in severe and end-stage glaucoma: preliminary results.

Authors:  Igor Leleu; Benjamin Penaud; Esther Blumen-Ohana; Thibault Rodallec; Raphaël Adam; Olivier Laplace; Jad Akesbi; Jean-Philippe Nordmann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-03       Impact factor: 3.117

4.  Refined Frequency Doubling Perimetry Analysis Reaffirms Central Nervous System Control of Chronic Glaucomatous Neurodegeneration.

Authors:  Matthew A Reilly; Analaura Villarreal; Ted Maddess; William Eric Sponsel
Journal:  Transl Vis Sci Technol       Date:  2015-06-08       Impact factor: 3.283

5.  Nonpenetrating Deep Sclerectomy for Progressive Glaucoma: Long-term (5-year) Follow-up of Intraocular Pressure Control and Visual Field Survival.

Authors:  Grant Slagle; Sylvia L Groth; Mario Montelongo; William E Sponsel
Journal:  J Curr Glaucoma Pract       Date:  2020 Jan-Apr

6.  Refined Data Analysis Provides Clinical Evidence for Central Nervous System Control of Chronic Glaucomatous Neurodegeneration.

Authors:  William E Sponsel; Sylvia L Groth; Nancy Satsangi; Ted Maddess; Matthew A Reilly
Journal:  Transl Vis Sci Technol       Date:  2014-05-06       Impact factor: 3.283

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.